12,372 trials
Influenza
Primary: Humoral Immune Response for Each Vaccine Strain in Terms of Haemagglutination Inhibition (HI) Antibody Titers. — 47.3; 31.2; 460.2; 166.9 Titers
Late Effects of Surgery · Staphylococcus Aureus · Surgical Site Infection
Primary: Mean Daptomycin Concentrations at 12, 18, 24, and 48 h — 22.7; 16.2; 12.0; 3.5 mcg/ml
Rheumatoid Arthritis
Primary: Percentage of Participants With an Adverse Event (AE) — 83 percentage of participants
Rheumatoid Arthritis
Primary: American College of Rheumatology 20% Response Criteria (ACR20) — 78.1; 80.5 percentage of participants
Rheumatoid Arthritis
Primary: American College of Rheumatology 20% Response Criteria (ACR20) — 64.1; 66.0 percentage of participants
Hepatitis D, Chronic
Primary: Percentage of Participants With Normal Alanine Aminotransferase (ALT) at Week 72 — 54.84 percentage of participants
Choroidal Neovascularization (CNV)
Primary: Change From Baseline in Best-corrected Visual Acuity (BCVA) in Study Eye to Month 2 — 9.5; -0.4 letters — p=<0.001
Hepatitis C
Primary: Percentage of Participants Maintaining Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Load Below the Level of Quantification (LOQ) Through Week 48 — 96.7; 99.5; 100.0…
Chronic Kidney Disease · Secondary Hyperparathyroidism · Vitamin D Insufficiency
Primary: Proportion (%) of Subjects With Serum 25-hydroxyvitamin D ≥30 ng/mL (PP). — 100; 100; 0; 91.7 percentage of participants — p=<0.0001
Fractures, Bone
Primary: Percent Change (Chg) From Baseline (BL) to Week (Wk)13 in Urinary Amino-terminal Cross-linking Telopeptide of Type I Collagen Corrected for Urine Creatinine (uNTx/uCr)…
Cardiovascular Disease
Primary: Composite of All-cause Mortality and Nonfatal MI — 173; 194; 178; 161 participants
Invasive Breast Carcinoma · Recurrent Breast Carcinoma · Stage III Breast Cancer AJCC v6
Primary: Progression-free Survival — 20.2; 15.6 months
Bipolar I Disorder
Primary: Treatment-emergent Adverse Events and Treatment-emergent Adverse Events Leading to Discontinuation and Serious Adverse Events — 155; 69; 14; 1 participants
Uveitis
Primary: Time to Treatment Failure on or After Week 6 — 3.0; 5.6; 3.0; 4.8 months — p=<0.001
Knee Osteoarthritis
Primary: Cartilage Volume Loss of the Lateral Compartment — 6408; 6196; 6196; 6143 cubic milimeters